99mTc-HYNIC-gastrin peptides: Assisted coordination of 99mTc by amino acid side chains results in improved performance both in vitro and in vivo

Journal of Nuclear Medicine

Volumn 50, Issue 4, 2009, Pages 591-598

  King, Robert ^a   Surfraz, M Bashir Uddin ^b   Finucane, Ciara ^a   Biagini, Stefano C G ^b   Blower, Philip J ^c   Mather, Stephen J ^a,d  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF KENT   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Coordination; HYNIC; Molecular imaging; Peptides; Radiopharmaceuticals; Technetium

Indexed keywords

CHOLECYSTOKININ RECEPTOR; ETHYLENEDIAMINEDIACETIC ACID; GASTRIN; GLUTAMIC ACID; GLYCINE; HISTIDINE; HYDRAZINONICOTINAMIDE; NICOTINAMIDE DERIVATIVE; RADIOLIGAND; TECHNETIUM 99M; TRICINE; UNCLASSIFIED DRUG; AMINO ACID; DIAGNOSTIC AGENT; OLIGOPEPTIDE; ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M HYNIC (LYSYL) GLUTAMYL ALANYL TYROSYL GLYCYL TRYPTOPHYL METHIONYL ASPARTYL PHENYLALANINAMIDE; TECHNETIUM 99M HYNIC (LYSYL) GLYCYL ALANYL TYROSYL GLYCYL TRYPTOPHYL METHIONYL ASPARTYL PHENYLALANINAMIDE; TECHNETIUM 99M HYNIC (LYSYL) GLYCYL HISTIDYL GLUTAMYL ALANYL TYROSYL GLYCYL TRYPTOPHYL METHIONYL ASPARTYL PHENYLALANINAMIDE; TECHNETIUM 99M HYNIC (LYSYL)-GLUTAMYL-ALANYL-TYROSYL-GLYCYL-TRYPTOPHYL-METHIONYL-ASPARTYL-PHENYLALANINAMIDE; TECHNETIUM 99M HYNIC (LYSYL)-GLYCYL-ALANYL-TYROSYL-GLYCYL-TRYPTOPHYL-METHIONYL-ASPARTYL-PHENYLALANINAMIDE; TECHNETIUM 99M HYNIC (LYSYL)-GLYCYL-HISTIDYL-GLUTAMYL-ALANYL-TYROSYL-GLYCYL-TRYPTOPHYL-METHIONYL-ASPARTYL-PHENYLALANINAMIDE; TECHNETIUM COMPLEX;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CARBOXY TERMINAL SEQUENCE; COMPLEX FORMATION; CONJUGATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; ISOTOPE LABELING; MASS SPECTROMETER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STABILITY; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; PROTEIN TARGETING; PROTEIN TRANSPORT; RECEPTOR AFFINITY; RECEPTOR BINDING; TUMOR; ANIMAL; ANTIBODY SPECIFICITY; CHEMISTRY; IMAGE ENHANCEMENT; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; NUDE MOUSE; PANCREAS TUMOR; SCINTISCANNING; SYNTHESIS; TISSUE DISTRIBUTION;

AMINO ACIDS; ANIMALS; IMAGE ENHANCEMENT; ISOTOPE LABELING; METABOLIC CLEARANCE RATE; MICE; MICE, NUDE; OLIGOPEPTIDES; ORGAN SPECIFICITY; ORGANOMETALLIC COMPOUNDS; ORGANOTECHNETIUM COMPOUNDS; PANCREATIC NEOPLASMS; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 63849266069     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.058289     Document Type: Article

References (20)

1. 99mTc-labeling, and in vitro characterization of HYNIC and N3S modified RC-160 and [Tyr3]octreotide. Bioconjug Chem. 1999;10:431-438.
2. Babich JW, Solomon H, Pike MC, et al. Tc-99m-labeled hydrazino- nicotinamide derivatized chemotactic peptide analogs for imaging focal sites of bacterial infection. J Nucl Med. 1993;34:1964-1974.
3. Liu S, Edwards DS, Looby RJ, et al. Labeling a hydrazino nicotinamide-modified cyclic Ilb/IIIa receptor antagonist with Tc-99m using aminocarboxylates as coligands. Bioconjug Chem. 1996;7:63-71.
4. Abrams MJ, Juweid M, Tenkate CI, et al. Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med. 1990;31:2022-2028.
5. King RC, Surfraz MB, Biagini SCG, Blower PJ, Mather SJ. How do HYNIC-conjugated peptides bind technetium? Insights from LC-MS and stability studies. Dalton Trans. 2007;43:4998-5007.
6. Liu S, Hsieh WY, Kim YS, Mohammed SI. Effect of coligands on biodistribution characteristics of ternary ligand Tc-99m complexes of a HYNIC-conjugated cyclic RGDfK dimer. Bioconjug Chem. 2005;16:1580-1588.
7. 99mTc-labelled peptides. Q J Nucl Med. 2002;46:195-205.
8. Babich JW, Coco WG, Barrow S, Fischman AJ, Femia FJ, Zubieta J. Tc-99m-labeled chemotactic peptides: influence of coligand on distribution of molecular species and infection imaging properties-synthesis and structural characterization of model complexes with the {Re(eta(2)-HNNC5H4N)(eta(1)- NNC5H4N)} core. Inorg Chim Acta. 2000;309:123-136.
9. Greenland WEP, Howland K, Hardy J, Fogelman I, Blower PJ. Solid-phase synthesis of peptide radiopharmaceuticals using Fmoc-N-epsilon-(Hynic-Boc)- lysine, a technetium-binding amino acid: application to Tc-99m-labeled salmon calcitonin. J Med Chem. 2003;46:1751-1757.
10. Surfraz MB, King RC, Mather SJ, Biagini SCG, Blower PJ. Technetium-binding in labelled HYNIC-peptide conjugates: role of coordinating amino acids [abstract]. Eur J Nucl Med Mol Imaging. 2007;34(suppl 2):S148.
11. 99mTc radiolabeling. J Med Chem. 2007;50:1418-1422.
12. Behe M, Reubi J, Nock B, Macke H, Breeman W, Bernard H. Evaluation of a DOTA-minigastrin derivative for therapy and diagnosis for CCK-2 receptor positive tumours [abstract]. Eur J Nucl Med Mol Imaging. 2005;32(suppl):S78.
13. 111In-labeled CCK-2/gastrin receptor-specific peptides in rats. Anticancer Res. 2007;27:907-912.
14. Good S, Walter MA, Waser B, et al. Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours. Eur J Nucl Med Mol Imaging. 2008;35:1868-1877.
15. Kichler A, Mason A, Bechinger B. Cationic amphipathic histidine-rich peptides for gene delivery. Biochim Biophys Acta. 2006;1758:301-307.
16. Mason A, Leborgne C, Moulay G, et al. Optimising histidine rich peptides for efficient DNA delivery in the presence of serum. J Control Release. 2007;118:95-104.
17. Mather SJ, McKenzie AJ, Sosabowski JK, Morris TM, Ellison D, Watson SA. Selection of radiolabeled gastrin analogs for peptide receptor-targeted radionuclide therapy. J Nucl Med. 2007;48:615-622.
18. 1]-minigastrin. Bioconjug Chem. 2004;15:864-871.
19. 99mTc-labelled HYNIC-minigastrin with reduced kidney uptake for targeting of CCK-2 receptor-positive tumours. Eur J Nucl Med Mol Imaging. 2007;34:1209-1218.
20. 99mTc-labeled minigastrin analogs. J Nucl Med. 2005;46:1727-1736